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C′-CEO SLOWS POST-TRAUMATIC OA PROGRESSION AND RELIEVES
OA-RELATED PAIN
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Purpose: There is currently no cure for osteoarthritis (OA) and no
therapy that will slow or arrest progression of this disease. Our previous
studies identiﬁed a transcriptional regulator, Cbp/p300 Interacting
Transactivator 2 (CITED2) that mediates chondroprotection, at least in
part by suppressing expression of proteases including the matrix met-
alloproteinase MMP-13 and the aggrecanase ADAMTS5. Using a tar-
geted screening approach, we found four nutraceuticals (carvacrol [C0],
curcumin [C], green tea polyphenol Epigallocatechin gallate [E], and
oligomeric proanthocyanidins [O]), that individually increased the
expression of CITED2 and reduced the expression of MMPs and
ADAMTS in human chondrocytes in vitro. The objective of the present
study was to determine the efﬁcacy of the combination of these
nutraceuticals (C0-CEO) in chondroprotection in vitro and in vivo using
an OA disease model that includes symptom modiﬁcation.
Methods:Human chondrocyte culture: Human chondrocytic cells (C28/
I2) were treated with Carvacrol (C0, 1mM), Curcumin (C, 1mM), EGCG (E,
100mM), OPC (O, 50mg/ml), or C0-CEO (combination of all 4 compounds)
for 24 hours in the presence of IL-1b (10ng/ml). Relative mRNA levels of
MMPs 1, 3,13, ADAMTS5, TNF-a, and CITED2were analyzed by real-time
PCR. n¼6. * p<0.05 using one-way ANOVA and Tukey post-hoc test.
Mice (C57BL/6, male, 6 months-old, n¼8/group) were subjected to
destabilization of the medial meniscus (DMM) and treated daily (7
days/week) with Carvacrol (C0: 50mg/kg), Curcumin (C: 50mg/kg),
Epigallocatechin gallate (E: 5mg/kg), oligomeric proanthocyanidins (O:
50mg/kg), C0-CEO (combination of all 4 compounds), or vehicle for 8
weeks via oral gavage with naïve mice as an additional control. OA
assessments: Arthritic pain was assessed at 8 weeks following DMM
surgery using assays of von Frey (mechanical allodynia) and open ﬁeld.
OA severity was evaluated by OARSI scoring of Safranin O-stained tissue
sections from decalciﬁed, formalin-ﬁxed hind limbs. Immunohis-
tochemistry was used to detect cleaved aggrecan and type II collagen in
the cartilage extracellular matrix and MMP-13, ADAMTS5, and CITED2
positive chondrocytes.
Results: In vitro, the combination treatment, C0-CEO, was more potent
than any individual compound in reducing mRNA levels of MMP-3,
MMP-13, ADAMTS-5 and TNF-a and increasing CITED2 mRNA (Fig 1),
indicating a synergistic chondroprotective effect of the 4 compounds as
a potential OA therapeutic. In vivo, while each individual compound
reduced OA disease progression, C0-CEO-treated mice exhibited the
lowest OA score and best preservation of the articular cartilage from
thinning and surface damage compared to that observed in vehicle-
treated DMM mice (Fig 2A). C0-CEO also protected against type II col-
lagen and aggrecan cleavage, and reduced MMP-13 and ADAMTS5
immunostaining (Fig 2B). Furthermore, C0-CEO treatment restored the
percentage of CITED2-positive chondrocytes from 28±3% (vehicle) to
55±6% (C0-CEO; C0-CEO vs. vehicle p<0.05), similar to that in naïve mice
(51±3%, Fig 2C). With regards to pain, C0-CEO-treated DMM mice, like
naïve controls, required a higher force to elicit pawwithdrawal (p<0.05,
Fig 3A), traveled a longer distance (p<0.05, Fig 3B), and increased
rearing (p<0.05, Fig 3C), indicating that C0-CEO exerted a signiﬁcant
relief of pain symptoms related to OA.
Conclusions: A novel nutraceutical formulation, C0-CEO, increases lev-
els of CITED2 and is effective in slowing OA progression and in relieving
OA-related pain in an OA animal model. These ﬁndings provide a
rational basis for advancing this product as an intervention for OA
prevention and treatment.545
THE EFFECTS OF TREATMENT ON DISEASE SYMPTOMS AND
PROGRESSION OF STRUCTURAL CHANGES IN KNEE
OSTEOARTHRITIS: PARTICIPANTS FROM THE OSTEOARTHRITIS
INITIATIVE PROGRESSION COHORT
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Purpose: The impact of meniscal extrusion on response to treatment
could be a clinically relevant concern in the context of personalized
management of osteoarthritis (OA).
The aim of this study was to evaluate the role of meniscal extrusion on
the effects of conventional OA pharmacological treatment and those of
glucosamine and chondroitin sulfate (Glu/CS) on knee structural
changes, using data from the progression cohort of the OA Initiative
(OAI).
The OAI allows the study of potential disease-modifying OA drug
(DMOAD) effects in patients over time following the evolution of OA
structural changes and the associated risk factors.
Methods: Participants (n¼600) were selected from the OAI progression
cohort (n¼1,390) if they had 24 consecutive months follow-up with
complete radiographic and magnetic resonance imaging (MRI) data for
the most symptomatic knee based on the highest WOMAC pain score at
the onset of the study (Time [T] 0).
Those participants were stratiﬁed into two main groups based on
whether (þ) or not (-) standard pharmacological treatment for OA
(analgesics and non-steroidal anti-inﬂammatory drugs [NSAIDs]) was
taken for disease symptoms over a continuous period of 24 months
